Protara Therapeutics closed a $100 million public offering to fund clinical development of its therapies.Quiver AI SummaryProtara Therapeutics, Inc. announced the completion of its public offering of 13,690,000...
Protara Therapeutics announced a public offering of common stock to fund clinical development programs.Quiver AI SummaryProtara Therapeutics, Inc. has announced the initiation of an underwritten public...
TARA-002 shows promising response rates in NMIBC patients, with favorable safety and tolerability in a Phase 2 trial.Quiver AI SummaryProtara Therapeutics, Inc. announced promising results from its Phase...
The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.
Protara Therapeutics will present interim Phase 2 trial data for TARA-002 in NMIBC on December 5, 2024.Quiver AI SummaryProtara Therapeutics, Inc. announced that it will host a conference call and live...